Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Invested Capital (2020 - 2025)

Historic Invested Capital for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $407.4 million.

  • Tarsus Pharmaceuticals' Invested Capital rose 3175.08% to $407.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $407.4 million, marking a year-over-year increase of 3175.08%. This contributed to the annual value of $296.4 million for FY2024, which is 3067.45% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Invested Capital stood at $407.4 million, which was up 3175.08% from $404.7 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Invested Capital ranged from a high of $414.4 million in Q1 2025 and a low of $166.7 million during Q4 2021
  • Over the past 5 years, Tarsus Pharmaceuticals' median Invested Capital value was $226.8 million (recorded in 2023), while the average stood at $256.1 million.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Invested Capital soared by 240248.81% in 2021 and then plummeted by 2842.21% in 2023.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Invested Capital stood at $166.7 million in 2021, then grew by 27.35% to $212.3 million in 2022, then rose by 6.82% to $226.8 million in 2023, then soared by 30.67% to $296.4 million in 2024, then skyrocketed by 37.45% to $407.4 million in 2025.
  • Its Invested Capital stands at $407.4 million for Q3 2025, versus $404.7 million for Q2 2025 and $414.4 million for Q1 2025.